MARLBOROUGH, Mass.,
Oct. 28, 2020 /PRNewswire/ -- Boston Scientific
Corporation (NYSE: BSX) generated sales of $2.659 billion during the third quarter of 2020.
This represents a decline of (1.8) percent on a reported basis,
(2.5) percent on an operational1 basis and (5.7) percent
on an organic2 basis, all compared to the prior year
period. The company reported a GAAP net loss available to common
stockholders of $(169) million or
$(0.12) per share (EPS), compared to
GAAP net income of $126 million or
$0.09 per share a year ago, and
achieved adjusted EPS of $0.37 for
the period, compared to $0.39 a year
ago.
"We have a robust cadence of new product launches across our
portfolio, and in the third quarter, we delivered strong sequential
improvement in our financial performance," said Mike Mahoney, chairman and chief executive
officer, Boston Scientific. "I am grateful to our global team for
their winning spirit and remain confident that our pipeline of
products and services positions us well to continue delivering
growth at the high end of our peer group."
Third quarter financial results and recent
developments:
- Included within organic sales results is a negative 230 basis
point impact associated with the conversion of U.S. WATCHMAN™
customers to a consignment inventory model and transition to the
next-generation WATCHMAN FLX™.
- Reported a GAAP net loss available to common stockholders of
$(0.12) per share and achieved
adjusted EPS of $0.37. The company
had not provided third quarter sales and EPS guidance due to
ongoing uncertainty associated with the scope and duration of the
COVID-19 pandemic.
-
- Included in adjusted EPS is a $(0.04) impact from WATCHMAN™ discussed above,
offset by a $0.06 tax
benefit3.
- Third quarter sales declined in each of our reportable
segments5, compared to the prior year period:
-
- MedSurg: (2.3) percent reported, (3.0) percent operational and
(1.9) percent organic
- Rhythm and Neuro: (3.0) percent reported, (3.9) percent
operational and organic
- Cardiovascular: (5.3) percent reported, (5.9) percent
operational and (10.4) percent organic
- Generated third quarter regional6 sales
growth/(declines), compared to the prior year period:
-
- U.S.: (4.2) percent reported and operational
- EMEA (Europe, Middle East and Africa): 0.8 percent reported and (2.9)
percent operational
- APAC (Asia-Pacific): (2.6)
percent reported and (4.1) percent operational
- Emerging Markets4: (10.3) percent reported and (7.1)
percent operational
- Received FDA approval for the AVVIGO™ Guidance System, a
tablet platform designed to provide ease of use and accuracy when
utilizing fractional flow reserve wires during percutaneous
coronary intervention procedures.
- Received FDA approval for the high bleeding risk indication for
the SYNERGY™ and SYNERGY™ XD Bioabsorbable Polymer
Drug-Eluting Stent Systems (excluding the recently launched 48
mm stent size).
- Obtained CE Mark and initiated a limited market release in
Europe of the WaveWriter
Alpha™ portfolio of spinal cord stimulator (SCS) systems,
consisting of four full-body MRI conditional, Bluetooth-enabled
devices to provide personalized treatment for chronic intractable
pain.7
- Obtained CE Mark and initiated a limited market release in
Europe of the fourth generation
Vercise Genus™ Deep Brain Stimulation (DBS) System to treat
the symptoms of Parkinson's disease, essential tremor and dystonia
by delivering precisely targeted electrical stimulation, with
full-body MRI conditional and Bluetooth capabilities to better meet
individuals' specific needs.8
- Commenced the full global launch of the SpyGlass™ Discover
Digital Catheter, the first single-use scope to enable
physicians to take a single-stage approach to diagnostic and
therapeutic procedures in the pancreaticobiliary system, including
treating patients with bile duct stones.
- Initiated the U.S. launch of the SpaceOAR Vue™ Hydrogel,
a next-generation hydrogel spacer that is designed to reduce the
side effects of prostate radiation therapy, while providing
clinicians with the added ability to view the spacer using
computerized tomography (CT) scans instead of magnetic resonance
imaging (MRI).
- Initiated the European launch of the ACURATE neo2™
Aortic Valve System, a new transcatheter aortic valve
implantation platform designed to minimize paravalvular leaking and
facilitate highly accurate positioning, for patients with aortic
stenosis.
- Received a New Technology Add-on Payment (NTAP) designation
from the U.S. Centers for Medicare and Medicaid Services for the
Eluvia™ Drug-Eluting Vascular Stent System, developed
for the treatment of PAD, providing eligible hospitals with
incremental reimbursement for the Eluvia stent system. The NTAP
designation is awarded to new medical devices determined to
substantially improve the diagnosis or treatment of Medicare
beneficiaries and went into effect on October 1, 2020.
- Announced an expanded investment and exclusive acquisition
option agreement with Farapulse, Inc., a privately-held company
developing a pulsed field ablation system for the treatment of
atrial fibrillation (AFib) and other cardiac arrhythmias via the
creation of a therapeutic electric field.
1. Operational
revenue growth excludes the impact of foreign currency
fluctuations.
|
2. Organic revenue
growth excludes the impact of foreign currency fluctuations and net
sales associated with our Q3 2019 acquisition of BTG plc (BTG) for
the period prior to mid-August, for which there were no prior
period net sales. Organic revenue growth also excludes the impact
of the divestiture of our global embolic microspheres portfolio, a
transaction entered into in connection with obtaining the antitrust
clearances required to complete the BTG transaction, also for the
period prior to mid-August, as well as prior period net sales
associated with our intrauterine health franchise, which we
divested in Q2 2020.
|
3. We recorded a
$0.06 non-cash tax benefit due to the resolution of the IRS
examination of our 2014 through 2016 tax years.
|
4. We define
Emerging Markets as the 20 countries that we believe have strong
growth potential based on their economic conditions, healthcare
sectors and our global capabilities.
|
5. We have three
historical reportable segments comprised of Medical Surgical
(MedSurg), Rhythm and Neuro, and Cardiovascular, which represent an
aggregation of our operating segments that generate revenues from
the sale of medical devices (Medical Devices). As part of our
acquisition of BTG on August 19, 2019, we acquired an
Interventional Medicine business, which is now included in our
Peripheral Interventions operating segment's revenues from the date
of acquisition. We have revised amounts for the third quarter of
2019 to conform to the current year presentation..
|
6. As part of our
acquisition of BTG on August 19, 2019, we acquired a specialty
pharmaceuticals business (Specialty Pharmaceuticals). Subsequent to
acquisition, Specialty Pharmaceuticals is now a stand-alone
operating segment presented alongside our Medical Device reportable
segments. We have revised amounts for the third quarter of 2019 to
conform to the current year presentation. Specialty Pharmaceuticals
net sales are substantially U.S. based. Our chief operating
decision maker (CODM) reviews financial information of our globally
managed Specialty Pharmaceuticals operating segment at the
worldwide level without further disaggregation into regional
results. As such, Specialty Pharmaceuticals net sales are presented
globally, and our Medical Devices reportable segments regional net
sales results do not include Specialty
Pharmaceuticals.
|
7. The WaveWriter
Alpha™ and WaveWriter Alpha™ Prime Spinal Cord Stimulator Systems
provide safe access to full-body 1.5T MRI scans when used
with specific components and exposed to the MRI environment under
the defined conditions in the ImageReady™ MRI Full Body Guidelines
for WaveWriter Alpha™ and WaveWriter Alpha™ Prime Spinal Cord
Stimulator Systems.
|
8. 1.5 Tesla MRI
conditional when all conditions of use are met.
|
Net sales for the third quarter by business and
region:
|
|
|
|
|
Change
|
|
|
Three Months
Ended
September 30,
|
|
Reported
Basis
|
|
Less:
Impact of
Foreign
Currency
Fluctuations
|
|
Operational
Basis
|
|
Less:
Impact of
Recent
Acquisitions /
Divestitures
|
|
Organic
Basis
|
(in
millions)
|
2020
|
2019*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Endoscopy
|
$
|
475
|
|
$
|
486
|
|
|
(2.1)%
|
|
0.9%
|
|
(3.0)%
|
|
—%
|
|
(3.0)%
|
|
Urology
and Pelvic Health
|
350
|
|
359
|
|
|
(2.6)%
|
|
0.4%
|
|
(3.0)%
|
|
(2.5)%
|
|
(0.5)%
|
|
MedSurg
|
825
|
|
845
|
|
|
(2.3)%
|
|
0.7%
|
|
(3.0)%
|
|
(1.1)%
|
|
(1.9)%
|
|
Cardiac
Rhythm Management
|
465
|
|
478
|
|
|
(2.7)%
|
|
1.0%
|
|
(3.7)%
|
|
—%
|
|
(3.7)%
|
|
Electrophysiology
|
76
|
|
81
|
|
|
(6.0)%
|
|
1.5%
|
|
(7.5)%
|
|
—%
|
|
(7.5)%
|
|
Neuromodulation
|
216
|
|
222
|
|
|
(2.5)%
|
|
0.5%
|
|
(3.0)%
|
|
—%
|
|
(3.0)%
|
|
Rhythm and
Neuro
|
757
|
|
780
|
|
|
(3.0)%
|
|
0.9%
|
|
(3.9)%
|
|
—%
|
|
(3.9)%
|
|
Interventional Cardiology
|
586
|
|
700
|
|
|
(16.3)%
|
|
0.5%
|
|
(16.8)%
|
|
—%
|
|
(16.8)%
|
|
Peripheral Interventions
|
416
|
|
358
|
|
|
16.1%
|
|
0.7%
|
|
15.4%
|
|
13.4%
|
|
2.0%
|
|
Cardiovascular
|
1,002
|
|
1,058
|
|
|
(5.3)%
|
|
0.6%
|
|
(5.9)%
|
|
4.5%
|
|
(10.4)%
|
|
Medical
Devices5
|
2,584
|
|
2,684
|
|
|
(3.7)%
|
|
0.7%
|
|
(4.4)%
|
|
1.5%
|
|
(5.9)%
|
|
Specialty
Pharmaceuticals6
|
74
|
|
23
|
|
|
n/a
|
|
n/a
|
|
n/a
|
|
n/a
|
|
11.0%
|
|
Net
Sales
|
$
|
2,659
|
|
$
|
2,707
|
|
|
(1.8)%
|
|
0.7%
|
|
(2.5)%
|
|
3.2%
|
|
(5.7)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*In the third
quarter of 2019, we presented Interventional Medicine and Specialty
Pharmaceuticals together as "BTG Acquisition" and outside of our
operating and reportable segments net sales. Following the
integration of BTG, we now include Interventional Medicine business
within our Peripheral Interventions operating segment, within the
Cardiovascular reportable segment. We present Specialty
Pharmaceuticals business as a standalone operating segment
alongside our reportable segments. We have revised amounts for the
third quarter of 2019 to conform to the current year
presentation.
|
|
|
|
|
|
|
|
|
Change
|
|
|
Three Months
Ended
September 30,
|
|
Reported
Basis
|
|
Less: Impact
of Foreign
Currency
Fluctuations
|
|
Operational
Basis
|
(in
millions)
|
2020
|
2019*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
|
1,496
|
|
$
|
1,561
|
|
|
(4.2)%
|
|
—%
|
|
(4.2)%
|
|
EMEA
|
540
|
|
535
|
|
|
0.8%
|
|
3.7%
|
|
(2.9)%
|
|
APAC
|
472
|
|
485
|
|
|
(2.6)%
|
|
1.5%
|
|
(4.1)%
|
|
Latin America and
Canada
|
77
|
|
102
|
|
|
(24.3)%
|
|
(7.7)%
|
|
(16.6)%
|
|
Medical
Devices5
|
2,584
|
|
2,684
|
|
|
(3.7)%
|
|
0.7%
|
|
(4.4)%
|
|
Specialty
Pharmaceuticals6
|
74
|
|
23
|
|
|
n/a
|
|
n/a
|
|
n/a
|
|
Net
Sales
|
$
|
2,659
|
|
$
|
2,707
|
|
|
(1.8)%
|
|
0.7%
|
|
(2.5)%
|
|
|
|
|
|
|
|
|
|
|
|
Emerging
Markets4
|
$
|
278
|
|
$
|
310
|
|
|
(10.3)%
|
|
(3.2)%
|
|
(7.1)%
|
|
|
|
|
|
|
|
|
|
|
|
*In the third
quarter of 2019, we presented Interventional Medicine and Specialty
Pharmaceuticals together as "BTG Acquisition" and outside of our
operating and reportable segments net sales. Following the
integration of BTG, we now include Interventional Medicine business
within our Peripheral Interventions operating segment, within the
Cardiovascular reportable segment. We present Specialty
Pharmaceuticals business as a standalone operating segment
alongside our reportable segments. We have revised amounts for the
third quarter of 2019 to conform to the current year
presentation.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amounts may not
add due to rounding. Growth rates are based on actual, non-rounded
amounts and may not recalculate precisely.
|
|
|
|
Sales growth rates
that exclude the impact of foreign currency fluctuations and/or the
impact of recent aforementioned acquisitions / divestitures are not
prepared in accordance with U.S. GAAP.
|
|
|
|
|
|
|
|
|
|
|
Conference Call Information
Boston Scientific management will be discussing these results
with analysts on a conference call today at 8:00 a.m. EDT. The company will webcast the call
to interested parties through its website:
www.bostonscientific.com. Please see the website for details on how
to access the webcast. The webcast will be available for
approximately one year on the Boston Scientific website.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for 40 years, we advance science for life by providing a
broad range of high performance solutions that address unmet
patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on
Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of
1934. Forward-looking statements may be identified by words
like "anticipate," "expect," "project," "believe," "plan,"
"estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates
using information available to us at the time and are not intended
to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding our business plans and product performance, and the
impact of the COVID-19 outbreak on the company's results of
operations. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections
expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together
with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially
from those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, political, competitive, reimbursement and
regulatory conditions; new product introductions; demographic
trends; intellectual property; litigation; financial market
conditions; and future business decisions made by us and our
competitors. All of these factors are difficult or impossible
to predict accurately and many of them are beyond our
control. For a further list and description of these and other
important risks and uncertainties that may affect our future
operations, see Part I, Item 1A - Risk Factors in our
most recent Annual Report on Form 10-K filed with the Securities
and Exchange Commission, which we may update in Part II, Item 1A
- Risk Factors in Quarterly Reports on Form 10-Q we have
filed or will file hereafter. We disclaim any intention or
obligation to publicly update or revise any forward-looking
statements to reflect any change in our expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking
statements. This cautionary statement is applicable to all
forward-looking statements contained in this document.
Note: Amounts reported in millions within this press
release are computed based on the amounts in thousands. As a
result, the sum of the components reported in millions may not
equal the total amount reported in millions due to rounding.
Certain columns and rows within tables may not add due to the use
of rounded numbers. Percentages presented are calculated from the
underlying numbers in dollars.
Use of Non-GAAP Financial Information
A
reconciliation of the company's non-GAAP financial measures to the
corresponding GAAP measures, and an explanation of the company's
use of these non-GAAP financial measures, is included in the
exhibits attached to this press release.
CONTACT:
|
|
|
|
|
Media:
|
Kate
Haranis
|
|
Investors:
|
Susie Lisa,
CFA
|
|
508-683-6585
(office)
|
|
|
508-683-5565
(office)
|
|
Media
Relations
|
|
|
Investor
Relations
|
|
Boston Scientific
Corporation
|
|
|
Boston Scientific
Corporation
|
|
kate.haranis@bsci.com
|
|
|
BSXInvestorRelations@bsci.com
|
BOSTON SCIENTIFIC
CORPORATION
CONDENSED
CONSOLIDATED GAAP RESULTS OF OPERATIONS
(Unaudited)
|
|
|
Three Months
Ended
September 30,
|
|
Nine Months
Ended
September 30,
|
in millions,
except per share data
|
2020
|
2019
|
|
2020
|
2019
|
|
|
|
|
|
|
Net sales
|
$
|
2,659
|
|
$
|
2,707
|
|
|
$
|
7,204
|
|
$
|
7,831
|
|
Cost of products
sold
|
869
|
|
777
|
|
|
2,465
|
|
2,265
|
|
Gross
profit
|
1,790
|
|
1,930
|
|
|
4,740
|
|
5,566
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
Selling, general and
administrative expenses
|
984
|
|
1,012
|
|
|
2,760
|
|
2,849
|
|
Research and
development expenses
|
315
|
|
306
|
|
|
857
|
|
866
|
|
Royalty
expense
|
12
|
|
15
|
|
|
32
|
|
48
|
|
Amortization
expense
|
197
|
|
178
|
|
|
595
|
|
498
|
|
Intangible asset
impairment charges
|
219
|
|
—
|
|
|
452
|
|
105
|
|
Contingent
consideration expense (benefit)
|
6
|
|
8
|
|
|
(102)
|
|
(9)
|
|
Restructuring charges
(credits)
|
3
|
|
3
|
|
|
16
|
|
10
|
|
Litigation-related net
charges (credits)
|
260
|
|
25
|
|
|
260
|
|
(108)
|
|
|
1,995
|
|
1,547
|
|
|
4,870
|
|
4,258
|
|
Operating income
(loss)
|
(205)
|
|
383
|
|
|
(130)
|
|
1,308
|
|
|
|
|
|
|
|
Other income
(expense):
|
|
|
|
|
|
Interest
expense
|
(86)
|
|
(95)
|
|
|
(265)
|
|
(294)
|
|
Other, net
|
64
|
|
(197)
|
|
|
9
|
|
(322)
|
|
Income
(loss) before income taxes
|
(227)
|
|
91
|
|
|
(386)
|
|
693
|
|
Income tax expense
(benefit)
|
(72)
|
|
(35)
|
|
|
(94)
|
|
(11)
|
|
Net income
(loss)
|
$
|
(155)
|
|
$
|
126
|
|
|
$
|
(292)
|
|
$
|
704
|
|
Preferred stock
dividends
|
(14)
|
|
—
|
|
|
(19)
|
|
—
|
|
Net income (loss)
available to common stockholders
|
$
|
(169)
|
|
$
|
126
|
|
|
$
|
(311)
|
|
$
|
704
|
|
|
|
|
|
|
|
Net income (loss)
per common share - basic
|
$
|
(0.12)
|
|
$
|
0.09
|
|
|
$
|
(0.22)
|
|
$
|
0.51
|
|
Net income (loss)
per common share - assuming dilution
|
$
|
(0.12)
|
|
$
|
0.09
|
|
|
$
|
(0.22)
|
|
$
|
0.50
|
|
|
|
|
|
|
|
Weighted-average
shares outstanding
|
|
|
|
|
|
Basic
|
1,430.9
|
|
1,393.1
|
|
|
1,413.0
|
|
1,390.6
|
|
Assuming
dilution
|
1,430.9
|
|
1,412.2
|
|
|
1,413.0
|
|
1,409.7
|
|
BOSTON SCIENTIFIC
CORPORATION
NON-GAAP NET INCOME
AND NET INCOME PER SHARE RECONCILIATIONS
(Unaudited)
|
|
|
Three Months Ended
September 30, 2020
|
|
(in millions,
except per share data)
|
Gross
Profit
|
Operating
Expenses
|
Operating
Income
(Loss)
|
Other
Income
(Expense)
|
Income (Loss)
Before
Income Taxes
|
Net Income
(Loss)
|
Preferred
Stock
Dividends
|
Net Income
(Loss)
Available to
Common
Stockholders
|
Impact
per
Share (1)
|
|
Reported
|
$
|
1,790
|
|
$
|
1,995
|
|
$
|
(205)
|
|
$
|
(22)
|
|
$
|
(227)
|
|
$
|
(155)
|
|
$
|
(14)
|
|
$
|
(169)
|
|
$
|
(0.12)
|
|
|
Non-GAAP
adjustments:
|
|
|
|
|
|
|
|
|
Amortization
expense
|
—
|
|
(197)
|
|
197
|
|
—
|
|
197
|
|
176
|
|
—
|
|
176
|
|
0.12
|
|
|
Intangible asset
impairment charges
|
—
|
|
(219)
|
|
219
|
|
—
|
|
219
|
|
189
|
|
—
|
|
189
|
|
0.13
|
|
|
Acquisition /
divestitures-related net charges (credits)
|
30
|
|
(90)
|
|
120
|
|
(9)
|
|
111
|
|
87
|
|
—
|
|
87
|
|
0.06
|
|
|
Restructuring and
restructuring-related net charges (credits)
|
15
|
|
(8)
|
|
23
|
|
—
|
|
23
|
|
21
|
|
—
|
|
21
|
|
0.01
|
|
|
Litigation-related net
charges (credits)
|
—
|
|
(260)
|
|
260
|
|
—
|
|
260
|
|
255
|
|
—
|
|
255
|
|
0.18
|
|
|
Investment impairment
charges (credits)
|
—
|
|
—
|
|
—
|
|
(65)
|
|
(65)
|
|
(50)
|
|
—
|
|
(50)
|
|
(0.03)
|
|
|
EU MDR implementation
costs
|
6
|
|
(2)
|
|
8
|
|
—
|
|
8
|
|
7
|
|
—
|
|
7
|
|
0.00
|
|
|
Deferred tax expenses
(benefits)
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
18
|
|
—
|
|
18
|
|
0.01
|
|
|
Discrete tax
items
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
(3)
|
|
—
|
|
(3)
|
|
(0.00)
|
|
|
Adjusted
|
$
|
1,841
|
|
$
|
1,220
|
|
$
|
621
|
|
$
|
(96)
|
|
$
|
525
|
|
$
|
543
|
|
$
|
(14)
|
|
$
|
530
|
|
$
|
0.37
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) For the three
months ended September 30, 2020, the effect of assuming the
conversion of Mandatory Convertible Preferred Stock (MCPS) into
shares of common stock was anti-dilutive, and therefore excluded
from the calculation of EPS. Accordingly, GAAP net loss and
adjusted net income were reduced by cumulative Preferred stock
dividends, as presented in our unaudited condensed consolidated
statements of operations, for purposes of calculating EPS. We have
assumed dilution of 13.6 million common stock equivalents related
to employee stock options for all or a portion of the non-GAAP
adjustments, which were anti-dilutive for GAAP purposes due to our
net loss position.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, 2019
|
|
(in millions,
except per share data)
|
Gross
Profit
|
Operating
Expenses
|
Operating
Income
(Loss)
|
Other
Income
(Expense)
|
Income (Loss)
Before
Income Taxes
|
Net Income
(Loss)
|
Preferred
Stock
Dividends
|
Net Income
(Loss)
Available to
Common
Stockholders
|
Impact
per
Share (1)
|
|
Reported
|
$
|
1,930
|
|
$
|
1,547
|
|
$
|
383
|
|
$
|
(292)
|
|
$
|
91
|
|
$
|
126
|
|
$
|
—
|
|
$
|
126
|
|
$
|
0.09
|
|
|
Non-GAAP
adjustments:
|
|
|
|
|
|
|
|
|
|
|
Amortization
expense
|
—
|
|
(178)
|
|
178
|
|
(2)
|
|
176
|
|
157
|
|
—
|
|
157
|
|
0.11
|
|
|
Intangible asset
impairment charges
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
0.00
|
|
|
Acquisition-related
net charges (credits)
|
28
|
|
(77)
|
|
105
|
|
199
|
|
304
|
|
236
|
|
—
|
|
236
|
|
0.17
|
|
|
Restructuring and
restructuring-related net charges (credits)
|
9
|
|
(6)
|
|
14
|
|
—
|
|
14
|
|
12
|
|
—
|
|
12
|
|
0.01
|
|
|
Litigation-related net
charges (credits)
|
—
|
|
(25)
|
|
25
|
|
—
|
|
25
|
|
19
|
|
—
|
|
19
|
|
0.01
|
|
|
Investment impairment
charges
|
—
|
|
—
|
|
—
|
|
1
|
|
1
|
|
1
|
|
—
|
|
1
|
|
0.00
|
|
|
EU MDR implementation
costs
|
2
|
|
—
|
|
2
|
|
—
|
|
2
|
|
2
|
|
—
|
|
2
|
|
0.00
|
|
|
Discrete tax
items
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
(2)
|
|
—
|
|
(2)
|
|
0.00
|
|
|
Adjusted
|
$
|
1,969
|
|
$
|
1,262
|
|
$
|
707
|
|
$
|
(94)
|
|
$
|
613
|
|
$
|
550
|
|
$
|
—
|
|
$
|
550
|
|
$
|
0.39
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
An explanation of
the company's use of these non-GAAP financial measures is provided
at the end of this document.
|
|
BOSTON SCIENTIFIC
CORPORATION
NON-GAAP NET INCOME
AND NET INCOME PER SHARE RECONCILIATIONS
(Unaudited)
|
|
|
Nine Months Ended
September 30, 2020
|
|
in millions,
except per share data
|
Gross
Profit
|
Operating
Expenses
|
Operating
Income
(Loss)
|
Other
Income
(Expense)
|
Income (Loss)
Before
Income Taxes
|
Net Income
(Loss)
|
Preferred
Stock
Dividends
|
Net Income
(Loss)
Available to
Common
Stockholders
|
Impact
per
Share (1)
|
|
Reported
|
$
|
4,740
|
|
$
|
4,870
|
|
$
|
(130)
|
|
$
|
(256)
|
|
$
|
(386)
|
|
$
|
(292)
|
|
$
|
(19)
|
|
$
|
(311)
|
|
$
|
(0.22)
|
|
|
Non-GAAP
adjustments:
|
|
|
|
|
|
|
|
|
|
|
Amortization
expense
|
—
|
|
(595)
|
|
595
|
|
—
|
|
595
|
|
533
|
|
—
|
|
533
|
|
0.38
|
|
|
Intangible asset
impairment charges
|
—
|
|
(452)
|
|
452
|
|
—
|
|
452
|
|
384
|
|
—
|
|
384
|
|
0.27
|
|
|
Acquisition /
divestitures-related net charges (credits)
|
97
|
|
(52)
|
|
149
|
|
(1)
|
|
148
|
|
100
|
|
—
|
|
100
|
|
0.07
|
|
|
Restructuring and
restructuring-related net charges (credits)
|
47
|
|
(30)
|
|
77
|
|
—
|
|
77
|
|
66
|
|
—
|
|
66
|
|
0.05
|
|
|
Litigation-related net
charges (credits)
|
—
|
|
(260)
|
|
260
|
|
—
|
|
260
|
|
255
|
|
—
|
|
255
|
|
0.18
|
|
|
Investment impairment
charges (credits)
|
—
|
|
—
|
|
—
|
|
(65)
|
|
(65)
|
|
(50)
|
|
—
|
|
(50)
|
|
(0.04)
|
|
|
EU MDR implementation
costs
|
14
|
|
(5)
|
|
20
|
|
—
|
|
20
|
|
17
|
|
—
|
|
17
|
|
0.01
|
|
|
Deferred tax expenses
(benefits)
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
26
|
|
—
|
|
26
|
|
0.02
|
|
|
Discrete tax
items
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
20
|
|
—
|
|
20
|
|
0.01
|
|
|
Adjusted
|
$
|
4,898
|
|
$
|
3,476
|
|
$
|
1,422
|
|
$
|
(322)
|
|
$
|
1,100
|
|
$
|
1,059
|
|
$
|
(19)
|
|
$
|
1,040
|
|
$
|
0.73
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) For the nine
months ended September 30, 2020, the effect of assuming the
conversion of Mandatory Convertible Preferred Stock (MCPS) into
shares of common stock was anti-dilutive, and therefore excluded
from the calculation of EPS. Accordingly, GAAP net loss and
adjusted net income were reduced by cumulative Preferred stock
dividends, as presented in our unaudited condensed consolidated
statements of operations, for purposes of calculating EPS. We have
assumed dilution of 14.1 million common stock equivalents related
to employee stock options for all or a portion of the non-GAAP
adjustments, which were anti-dilutive for GAAP purposes due to our
net loss position.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
September 30, 2019
|
|
in millions,
except per share data
|
Gross
Profit
|
Operating
Expenses
|
Operating
Income
(Loss)
|
Other
Income
(Expense)
|
Income (Loss)
Before
Income Taxes
|
Net Income
(Loss)
|
Preferred
Stock
Dividends
|
Net Income
(Loss)
Available to
Common
Stockholders
|
Impact
per
Share (1)
|
|
Reported
|
$
|
5,566
|
|
$
|
4,258
|
|
$
|
1,308
|
|
$
|
(615)
|
|
$
|
693
|
|
$
|
704
|
|
$
|
—
|
|
$
|
704
|
|
$
|
0.50
|
|
|
Non-GAAP
adjustments:
|
|
|
|
|
|
|
|
|
|
|
Amortization
expense
|
—
|
|
(498)
|
|
498
|
|
—
|
|
498
|
|
444
|
|
—
|
|
444
|
|
0.31
|
|
|
Intangible asset
impairment charges
|
—
|
|
(105)
|
|
105
|
|
—
|
|
105
|
|
97
|
|
—
|
|
97
|
|
0.07
|
|
|
Acquisition /
divestitures-related net charges (credits)
|
60
|
|
(114)
|
|
174
|
|
331
|
|
505
|
|
391
|
|
—
|
|
391
|
|
0.28
|
|
|
Restructuring and
restructuring-related net charges (credits)
|
18
|
|
(20)
|
|
38
|
|
—
|
|
38
|
|
31
|
|
—
|
|
31
|
|
0.02
|
|
|
Litigation-related net
charges (credits)
|
—
|
|
108
|
|
(108)
|
|
—
|
|
(108)
|
|
(96)
|
|
—
|
|
(96)
|
|
(0.07)
|
|
|
Investment impairment
charges (credits)
|
—
|
|
—
|
|
—
|
|
3
|
|
3
|
|
3
|
|
—
|
|
3
|
|
0.00
|
|
|
EU MDR implementation
costs
|
2
|
|
—
|
|
2
|
|
—
|
|
2
|
|
2
|
|
—
|
|
2
|
|
0.00
|
|
|
Discrete tax
items
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
16
|
|
—
|
|
16
|
|
0.01
|
|
|
Adjusted
|
$
|
5,645
|
|
$
|
3,629
|
|
$
|
2,016
|
|
$
|
(281)
|
|
$
|
1,736
|
|
$
|
1,590
|
|
$
|
—
|
|
$
|
1,590
|
|
$
|
1.13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
An explanation of
the company's use of these non-GAAP financial measures is provided
at the end of this document.
|
|
Use of Non-GAAP Financial Measures
To supplement our unaudited condensed consolidated financial
statements presented on a GAAP basis, we disclose certain non-GAAP
financial measures, including adjusted net income (loss), adjusted
net income (loss) available to common stockholders and adjusted net
income (loss) per share (EPS) that exclude certain amounts,
operational net sales, which exclude the impact of foreign currency
fluctuations and organic net sales, which exclude the impact of
foreign currency fluctuations and the impact of recent
aforementioned acquisitions and divestitures. These non-GAAP
financial measures are not in accordance with generally accepted
accounting principles in the United
States and should not be considered in isolation from or as
a replacement for the most directly comparable GAAP financial
measures. Further, other companies may calculate these non-GAAP
financial measures differently than we do, which may limit the
usefulness of those measures for comparative purposes.
To calculate adjusted net income (loss), adjusted net income
(loss) available to common stockholders and adjusted net income
(loss) per share we exclude certain charges (credits) from GAAP net
income and GAAP net income available to common stockholders.
Amounts are presented after-tax at the company's effective tax
rate, unless the amount is a significant unusual or infrequently
occurring item in accordance with FASB Accounting Standards
Codification section 740-270-30, "General Methodology and Use of
Estimated Annual Effective Tax Rate." Please refer to Part II, Item
7. Management's Discussion and Analysis of Financial Condition and
Results of Operations in our most recent Annual Report filed on
Form 10-K filed with the Securities and Exchange Commission or any
Quarterly Report on Form 10-Q that we file thereafter for an
explanation of each of these adjustments and the reasons for
excluding each item.
The GAAP financial measures most directly comparable to adjusted
net income (loss), adjusted net income (loss) available to common
stockholders and adjusted net income (loss) per share are GAAP net
income (loss), GAAP net income (loss) available to common
stockholders and GAAP net income (loss) per common share - assuming
dilution, respectively.
To calculate operational net sales growth rates, which exclude
the impact of foreign currency fluctuations, we convert actual net
sales from local currency to U.S. dollars using constant foreign
currency exchange rates in the current and prior period. To
calculate organic net sales growth rates, we remove the impact of
recent aforementioned acquisitions with no prior period related net
sales from operational net sales. In addition, to calculate organic
net sales growth rates, we remove from prior year, sales from
product lines that we divested. The GAAP financial measure most
directly comparable to operational net sales and organic net sales
is net sales on a GAAP basis.
Reconciliations of each of these non-GAAP financial measures to
the corresponding GAAP financial measure are included in the
accompanying schedules.
Management uses these supplemental non-GAAP financial measures
to evaluate performance period over period, to analyze the
underlying trends in our business, to assess our performance
relative to our competitors and to establish operational goals and
forecasts that are used in allocating resources. In addition,
management uses these non-GAAP financial measures to further its
understanding of the performance of our operating segments. The
adjustments excluded from our non-GAAP financial measures are
consistent with those excluded from our operating segments'
measures of net sales and profit or loss. These adjustments are
excluded from the segment measures reported to our chief operating
decision maker that are used to make operating decisions and assess
performance.
We believe that presenting adjusted net income (loss) available
to common stockholders, adjusted net income (loss) per share ,
operational net sales and organic net sales, in addition to the
corresponding GAAP financial measures, provides investors greater
transparency to the information used by management for its
operational decision-making and allows investors to see our results
"through the eyes" of management. We further believe that providing
this information assists our investors in understanding our
operating performance and the methodology used by management to
evaluate and measure such performance.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/boston-scientific-announces-results-for-third-quarter-2020-301161250.html
SOURCE Boston Scientific Corporation